A Phase 1, Open-Label, Positron Emission Tomography Study in Healthy Subjects to Determine D-Amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-Dose Oral Administration
Phase of Trial: Phase I
Latest Information Update: 10 Feb 2017
At a glance
- Drugs TAK 831 (Primary)
- Indications Ataxia; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Takeda
- 04 Oct 2016 Status changed from recruiting to completed.
- 21 Jul 2016 Status changed from not yet recruiting to recruiting.
- 28 Mar 2016 New trial record